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Parechoviruses are small, nonenveloped, single-stranded RNA viruses belonging to the family Picornaviridae. 
Although most human parechovirus (HPeV) infections 
cause self-limiting mild respiratory or gastrointestinal 
symptoms, HPeV type 3 (HPeV3) has been found in 5%–
13% of newborns and young infants <3 months of age 
with late-onset sepsis or encephalitis (1–12). Knowledge 
of HPeV3 infections originates from single cases or small 
series of sporadic unrelated infections. One considerable 
outbreak, affecting ≈200 infants with obviously communi-
ty-acquired diseases, was recently reported from Australia 
(1,2). In contrast, we describe a timely confined, and appar-
ently nosocomial, outbreak of HPeV3 infection originat-
ing from 1 maternity ward in Austria, affecting one fifth of 
newborns hospitalized during that period. 
The Study
During August 5–September 7, 2014, a total of 9 newborns, 
2–27 (median 5) days of age, showed signs of sepsis-like 
illness (fever and reduced general condition) and were ad-
mitted to the Department of Paediatrics and Adolescent 
Medicine, Medical University of Graz, Graz, Austria. All 
had been delivered within 2 weeks in the same obstetric 
unit at the Regional Hospital Feldbach, which is located 
in a small town (4,500 inhabitants) in southeastern Styria, 
a region of southern Austria of which Graz is the capital. 
During these 2 weeks, 44 newborns had been delivered at 
this obstetric unit (total 1,400/y); 9 (20.5%) born during 
these 2 weeks became symptomatic (Table; Figure). Diag-
nostic procedures were performed at the discretion of each 
attending physician and comprised testing for adenovirus, 
enterovirus, norovirus, rotavirus, herpesvirus 1, herpesvi-
rus 2, varicella zoster virus, Epstein-Barr virus, cytomega-
lovirus, human herpesvirus 6, and parvovirus B19. How-
ever, no causative agent was identified.
Because the only pediatric department in southern 
Styria (including Feldbach) is at the Medical University 
of Graz, all severely ill newborns or infants are admitted 
there. However, no additional cases of sepsis or sepsis-like 
illness of unclear etiology were identified in newborns or 
young infants from that area during these months. The facts 
that the outbreak was temporally confined and all affected 
patients had been nursed in the same ward strongly indicat-
ed a common source within this unit. Investigations to de-
tect a possible common source in the affected obstetric unit 
comprised anamnestic and clinical examination of hospital 
staff members and the newborns’ mothers, surface swab-
bing (e.g. nursery rooms, baby baths, examination beds, 
diaper changing tables), microbiological examinations of 
formula, and analysis of staff roster and occupancy plans. 
However, a presumed common source or causative agent 
could not be identified.
To further seek the causative pathogen, we analyzed 
serum, urine, and nasal secretions from 4 patients (nos. 4, 
6, 7, 8; Figure) by negative staining in a transmission elec-
tron microscope (Zeiss 906, Oberkochen, Germany) at 80 
kv. Although nasal secretions revealed no particles, serum 
and urine of 2 of the tested patients (nos. 6, 8) contained 
icosahedral particles, diameter 20–30 nm, resembling pi-
cornaviruses. Because of the young ages of the patients, we 
assumed that the particles were HPeVs. However, by the 
time we received the electron microscope results indicating 
picornaviruses, all affected patients had been discharged. 
We therefore requested fecal samples from all 9 discharged 
patients for molecular diagnostics of HPeV. We received 
samples from 4 patients (nos. 5, 6, 7, 9) a median of 29 days 
(range 9–34) after discharge. 
RNA was isolated by using a QIAamp Viral RNA Mini 
Kit (QIAGEN, Hilden, Germany) according to the manufac-
turer’s instructions. For HPeV detection, we used a real-time 
reverse transcription PCR (RT-PCR) selective for the 5′ non-
translated region as described (13,14). Molecular typing of 
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positive samples was conducted by nested real-time RT-PCR 
and sequencing of the partial capsid viral protein (VP) 3/VP1 
region by using primers described by Harvala et al. (15). We 
performed reverse transcription and first-round amplification 
by using a One-Step RT-PCR Kit (QIAGEN). Nested ampli-
fication was performed by using a HotStarTaq Master Mix 
Kit (QIAGEN). The resulting fragment (≈300 bp) was subse-
quently sequenced by using a BigDye Terminator v.3.1 Cy-
cle Sequencing Kit (Applied Biosystems/Life Technologies, 
Darmstadt, Germany) and nested PCR primers. Sequences 
were aligned to reference sequences in GenBank by using a 
BLAST (http://blast.ncbi.nlm.nih.gov//Blast.cgi) algorithm 
(online Technical Appendix, http://wwwnc.cdc.gov/EID/
article/22/9/15-1497-Techapp1.pdf). 
Of the 4 fecal samples tested, 3 were positive for 
HPeV. Molecular typing that used partial VP3/VP1 cap-
sid protein regions revealed HPeV3 in all 3 samples. To 
analyze the presence of this pathogen even during acute ill-
ness, we retrieved archived serum samples from 5 patients 
(nos. 2, 3, 5, 6, 7; Figure). No samples had been retained 
for 3 other patients. For 4 of the 5 patients tested, archived 
serum samples were positive for HPeV-3, indicating 
systemic infection with HPeV3 during the symptomatic 
phase of disease. Comparison of all 7 sequences (from 3 
fecal samples and 4 serum samples) revealed 100% iden-
tity. Resulting sequences were submitted to GenBank (ac-
cession nos. KU556748–KU556754).
Clinical signs and symptoms and laboratory changes 
for these 9 patients were compatible with those published 
for patients with HPeV3 infection (1,2). All 9 newborns re-
covered without complications; no severe, long-term com-
plications were noted 15 months later.
Despite intensive epidemiologic evaluation, we were 
not able to identify a human (personnel, mothers, siblings, 
or visitors) or nonhuman (surfaces, formula) source of in-
fection within this ward. However, because the causative 
agent was identified several weeks after the end of the out-
break, testing for HPeV had not been performed on any such 
human or environmental specimens. Therefore, we are not 
able to clearly differentiate common-source infection from 
person-to-person transmission. Because newborns do not 
have direct contact with each other, an asymptomatic adult 
or older sibling might have been the unidentified common 





Characteristic No.	(%)	patients Median	(range)† 
Demographic   
 Male	sex 5	(55.6) NA 
 Gestational	age,	wk	+	d NA 40	+	1	(38	+	3	to	41	+	2)	 
 Birth	weight,	g NA 3,480	(3,240–4,160)	 
 Vaginal	delivery 6	(66.7)  
 Age	at	onset	of	fever,	d NA 6	(1–27)	 
 Age	at	admission	to	PD,	d NA 6	(2–27)	 
Time	from	discharge	from	maternity	to	admission to	PD,	d NA 1	(0–24)	 
Clinical   
 Fever 9	(100) 39.1°C	(38.5°C–39.9°C) 
 Reduced	general	condition 4	(44.4) NA 
 Tachypnea 4	(44.4) NA 
 Tachycardia 3	(33.3) NA 
 Drinking	difficulties 5	(55.6) NA 
 Circulatory	centralization 3	(33.3) NA 
 Increased	irritability 3	(33.3) NA 
Treatment   
 Admission	to	NICU	or	PICU 3	(33.3) NA 
 Antimicrobial	drug	treatment, cefuroxime	+	amoxicillin 8	(88.9) 3	(25)	d 
 Intravenous	hydration 4	(44.4) NA 
 Length	of	stay	at	PD,	d NA 3	(09) 
Laboratory	values   
 Leukocytes, cells/μL NA 7,690	(4,750–18,310) 
 Granulocytes, cells/μL NA 4,595	(1,300–10,124) 
 Lymphocytes, cells/μL NA 2,330	(590–7,100) 
 Lymphopenia, <2,000 cells/μL 4	(44.4) NA 
 Monocytes, cells/μL NA 1,100	(660–2,470) 
 Minimal thrombocytes/μL NA 200,000	(101,000–270,000) 
 C-reactive	protein,	mg/L‡ NA 1.6	(<0.6–11.4) 
 C-reactive	protein	>5	mg/L 2	(22.2) NA 
 Procallcitonin,	ng/mL§ NA 0.18,	0.18,	and	0.36	 
 Interleukin-6,	pg/mL¶ NA 21.0	and	124.8	 
*NA,	not	applicable;	NICU,	neonatal	intensive	care	unit;	PD,	pediatric	department;	PICU,	pediatric	intensive	care	unit. 
†Unless	otherwise	indicated. 





infections with HPeV in adults are asymptomatic. Of the 9 
newborns, 4 became symptomatic while still hospitalized; 
thus, they were certainly infected while in the maternity 
ward. The other 5 became symptomatic after discharge 
from the obstetric unit, so they might have acquired the 
infection while outside the hospital. However, the interval 
between discharge and readmission was <1 week for all but 
1 patient, and no cases of community-acquired sepsis and 
sepsis-like illness in newborns or infants from that region 
without association with the affected maternity ward could 
be identified during that period. 
Thus, the infection was most likely nosocomial for at 
least 8 of the 9 patients. Assuming the period of infection 
for these patients (i.e., during their stay in the maternity 
ward), we can draw conclusions with regard to the incu-
bation period of HPeV3 infections. The observed intervals 
between infection and appearance of symptoms were from 
1 to 12 days. Only patient 9 became symptomatic 27 days 
after discharge; this patient might have acquired the infec-
tion outside the hospital.
Conclusions
For newborns, HPeV3 is a relevant pathogen; febrile illness 
appears as sepsis. After symptomatic infection, a newborn 
can shed HPeV3 in feces for at least 1 month. The conta-
gious nature of the virus can lead to nosocomial outbreaks. 
Thus, timely identification of the causative agent may 
prevent nosocomial transmission (by isolation and iden-
tification of the source) and unnecessary treatment with 
antimicrobial drugs. For newborns with sepsis-like illness, 
routine diagnostic considerations should include HPeV3.
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